Protective effect of ulinastatin combined with dexmedetomidine on perioperative liver ischemia-reperfusion injury in patients undergoing laparoscopic controlled low central venous pressure undergoing liver resection for liver cancer

Protective effect of ulinastatin combined with dexmedetomidine on perioperative liver ischemia-reperfusion injury in patients undergoing laparoscopic controlled low central venous pressure undergoing liver resection for liver cancer - The protective effect of ulinastatin combined with dexmedetomidine on perioperative HIRI in patients undergoing laparoscopic CLCVP liver resection for liver cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200056487

Enrollment

Unknown

Registered

2022-02-06

Start date

2022-02-07

Completion date

Unknown

Last updated

2024-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic ischemia-reperfusion injury

Interventions

Control group:Normal saline

Dexmedetomidine group:Dexmedetomidine continuous pumping

Ulinastatin combined with dexmedetomidine group:Ulinastatin pretreatment + dexmedetomidine continuous pumping

Eligibility

Sex/Gender

All

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 30 to 65 years old; 2. The diagnosis of liver cancer meets the relevant diagnostic criteria in the "Expert Consensus on the Standardized Diagnosis and Treatment of Primary Liver Cancer", and the postoperative pathological result is hepatocellular carcinoma; 3. Proposed laparoscopic liver resection (the scope of resection is not less than one liver segment); 4. It is expected that intraoperative hepatic portal blood flow occlusion method (Pringle method) and controlled low central venous pressure (CLCVP) will be used to control intraoperative bleeding; 5. Child-Pugh classification of liver function AB before operation; 6. ASA classification II-III grade; 7. The patient and family members have informed consent and signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Severe heart, lung and kidney disease; 2. Abnormal hemostasis function; 3. The tumor has invaded important blood vessels or bile ducts of the hepatic hilar; 4. Combined with distant metastasis or invasion of surrounding organs; 5. People with poor compliance such as mental illness, alcoholism, drug abuse, drug addiction, etc.; 6. Transit to laparotomy; 7. Suspend or terminate CLCVP during liver resection due to various reasons; 8. Evaluation by clinicians is not suitable for ulinastatin or dexmedetomidine; 9. Patients who are unwilling to participate in this study for any reason.

Design outcomes

Primary

Measure	Time frame
a-GST;	—

Secondary

Measure	Time frame
MDA;TNF-a;IL-6;ALT; AST;BUN; Cr;Complications (liver failure, acute kidney injury and death);Hospital stay;	—

Countries

China

Contacts

Public ContactLiu Gang

The First Affiliated Hospital of Bengbu Medical College

Liu_gang03@163.com+86 13956350877

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026